Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Blood Loss, Surgical
Interventions: Ecallantide, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more

Conditions: Dry Eye
Interventions: Ocular Surface Immune Globulin (OSIG), Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 28 more

Conditions: Hip Fractures
Interventions: Tranexamic Acid (TXA), Saline solution; Drug
Lead sponsor: Gregory M Georgiadis MD; Other
Eligibility: 60 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Preterm Premature Rupture of Membranes
Interventions: Magnesium sulfate; Drug
Lead sponsor: Regional Obstetrical Consultants; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Septic Shock
Interventions: Levo-Carnitine, placebo; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Sacramento, California • Wilmington, Delaware + 9 more

Conditions: Severe Hypertriglyceridemia
Interventions: Plozasiran Injection, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 52
States / cities: Garden Grove, California • Lake Forest, California • Montclair, California + 42 more

Conditions: Cirrhosis, Ascites Hepatic
Interventions: Albumin infusion (25% albumin), Normal Saline (0.9% NaCl); Drug
Lead sponsor: Anahita Rabiee MD MHS; Federal
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Knee Osteoarthritis
Interventions: Placebo, Dextrose prolotherapy (DPT); Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: 0.5 mL Candin®/injection, Placebo: 0.5 mL Intravenous 0.9% NaCl solution (Saline); Biological · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 6
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 3 more

Conditions: Trigeminal Neuralgia
Interventions: Incobotulinumtoxina, Placebo Comparator; Biological · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lateral Canthus Rhytides, Crow's Feet Lines
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Dengue
Interventions: YF-17D, TDV, Placebo; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Mobile, Alabama • Pomona, California • Meridian, Idaho + 8 more

Conditions: Yellow Fever
Interventions: HydroVax-002 YFV, Placebo; Biological · Other
Lead sponsor: Najit Technologies, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hemorrhage, Surgical, Tonsillar Bleeding
Interventions: Tranexamic Acid Injectable Product, Normal Saline; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 2 Years to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cholera (Disorder)
Interventions: VAXCHORA (Cholera Vaccine, Live, Oral), Placebo; Biological · Other
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 550 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Atlanta, Georgia • Lenexa, Kansas • Wichita, Kansas + 7 more

Conditions: Lyme Disease
Interventions: VLA15, Normal Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,547 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 65
States / cities: Birmingham, Alabama • Guntersville, Alabama • Bellflower, California + 55 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Placebo, [11C]raclopride plus drug, [11C]NNC-112; Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder
Interventions: GLYX-13 5 mg/kg, GLYX-13 10 mg/kg, Placebo; Drug
Lead sponsor: Naurex, Inc, an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Birmingham, Alabama • Encino, California • Los Alamitos, California + 21 more

Conditions: Lumbar Post-Laminectomy Syndrome, Chronic Low Back Pain, Vertebral Compression Fracture, Failed Back Surgery Syndrome
Interventions: Continuous intrathecal prognostic infusion test, Bupivacaine, Fentanyl, Placebo, Intrathecal Drug Delivery System (IDDS); Other · Drug · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Systemic Sclerosis
Interventions: Belimumab, Mycophenolate Mofetil, Placebo Infusion; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Tumor
Interventions: IV Acetaminophen, Saline Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: OTC Deficiency
Interventions: DTX301, Placebo, Oral Corticosteroids, Placebo for oral corticosteroids, Sodium Acetate; Genetic · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 12 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more

Conditions: Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease
Interventions: DCR-PHXC, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 6 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: San Francisco, California • Boston, Massachusetts • Rochester, Minnesota + 2 more

Search by objective public record fields.

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

OSIG-eye Drops Treatment for Dry Eye Disease

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion

Magnesium Sulfate Versus Placebo for Tocolysis in PPROM

Rapid Administration of Carnitine in sEpsis

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

Intraarticular Dextrose Prolotherapy for Symptomatic Knee Osteoarthritis

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Incobotulinum Toxin for the Treatment of Trigeminal Neuralgia

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults

Trial of an Inactivated Yellow Fever Virus Vaccine

TranExamic Atomized for Pediatric Post-Operative Tonsillectomy Hemorrhage: Pilot Study

VAXCHORA Pediatric Study to Assess Safety and Immunogenicity

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Determining the Prognostic Value of Continuous Intrathecal Infusion

Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis

Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2